Shiyao Group (01093.HK): Anituximab monoclonal antibody (KN026) combined with injection of albumin-bound doxorubicin (HB1801) in the first-line treatment of HER2-positive advanced breast cancer reached the primary endpoint in Phase III study.

Widsom Financial News App Update: Shi Pharma Group (01093.HK) announced that its subsidiary Shanghai Jinmant Biotechnology Co., Ltd. (Jinmant Biotechnology) has successfully achieved the pre-set primary endpoint of progression-free survival (PFS) in the phase III clinical trial (study protocol number: KN026-003) for the first-line treatment of HER2-positive advanced breast cancer with the combination of the independently developed monoclonal antibody KN026 and the injection form of docetaxel developed by the group (HB1801). The results have significant statistical and clinical implications, as well as good safety profile.